Market Research Report
Global Prostate Cancer Therapeutics Market 2019-2025
|Global Prostate Cancer Therapeutics Market 2019-2025|
Published: December 20, 2019
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy) and Forecast 2019-2025
The global prostate cancer therapeutics market has witnessed optimistic growth owing to the rising incidence rate of prostate cancer, robust R&D exploration and grants and investment for discovery of potential alternatives for prostate cancer treatment. Prostate cancer is an androgen-dependent disease that responds to medicine and treatment in the initial stages, however, in the later stages, it becomes resistant to therapies and other treatments. There are certain causes of prostate cancer which includes age, ethnicity, family history and genes, being overweight or obese, IGF-1 (Insulin such as growth factor), vasectomy, and inflammation of the prostate and others.
The US contributes highest in the prostate cancer treatment market owing to the significant prevalence of prostate cancer and the presence of well-developed healthcare infrastructure in the country. The rising adoption of minimally invasive surgeries is contributing to the demand for laparoscopic, brachytherapy, cryosurgical ablation and robotic radical prostatectomy for the treatment of prostate cancer. Other factors that are boosting the global prostate cancer therapeutics market includes R&D, rise in grants and funding, increasing adoption of personalized medicines, growing pharmaceutical industries and others. Further, successful clinical trials and FDA approval will influence the market growth in the near future.
North America and Europe have considerable contribution in the growth of the market followed by Asia-Pacific region. The key driving forces include rising incidence and prevalence of prostate cancer and adoption of innovative surgeries and treatment across the globe. Economies such as China, India, Japan, and South Korea have huge population of cancer patients. Technological advancement, innovation, and improved healthcare spending are anticipated to drive the growth of Asia-Pacific region. Improved standard of living, infrastructural development, and favorable government policies are some other factors that spur the regional growth of the market.
Some of the key players contributing significantly in the growth of prostate cancer therapeutics market include Sanofi S.A., Bayer AG, Astellas Pharma Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., and AstraZeneca PLC. The market players are constantly focusing on product launch, R&D, partnerships and collaborations, and mergers and acquisitions.
The market study of the global prostate cancer therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.
Secondary Sources Include:
The report is intended for cancer diagnostics, treatment and therapies providers, cancer drug manufacturers, pharmaceutical companies, healthcare organization, existing companies, and new entrants, potential investors and venture capitalists, research organizations, and government agencies and regulatory bodies for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, products offered by the company, and future market opportunity. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
The Report covers: